双歧杆菌乳杆菌三联活菌临床应用循证评价

Evidence-Based Evaluation of the Clinical Application of Live Combined Bifidobacterium and Lactobacillus

目的探讨双歧杆菌乳杆菌三联活菌临床应用的有效性、安全性和经济性。方法计算机检索The Cochrane Library,Embase,PubMed,CBM及中国知网等数据库中临床应用双歧杆菌乳杆菌三联活菌的相关文献,检索时间为自建库起至2021年4月21日,根据纳入与排除标准提取相关数据并分析。结果共纳入126项研究,临床多用双歧杆菌乳杆菌三联活菌治疗小儿腹泻、新生儿高胆红素血症等儿科疾病,肝硬化、非酒精性脂肪性肝病等肝胆系统疾病,幽门螺杆菌感染、急性胰腺炎等消化系统疾病,支气管哮喘等呼吸系统疾病,且有效性和安全性均较好,但尚无针对该药品使用的经济性评价。结论双歧杆菌乳杆菌三联活菌适应证范围较广,且有效性和安全性均较好,但经济性尚需进一步研究。

Objective To investigate the efficacy,safety and economy of the clinical application of Live Combined Bifidobacterium and Lactobacillus.Methods The relevant studies on the clinical application of Live Combined Bifidobacterium and Lactobacillus in The Cochrane Library,Embase,PubMed,CBM and CNKI databases were searched from the inception to April 21 st,2021,the relevant data were extracted and analyzed according to the inclusion criteria and exclusion criteria in the relevant studies.Results A total of 126 studies were included.Live Combined Bifidobacterium and Lactobacillus were mainly used to treat pediatric diseases such as pediatric diarrhea and neonatal hyperbilirubinemia,hepatobiliary diseases such as cirrhosis and non-alcoholic fatty liver disease,digestive diseases such as Helicobacter pylori infection and acute pancreatitis,and respiratory diseases such as bronchial asthma.The efficacy and safety of Live Combined Bifidobacterium and Lactobacillus were good,but there was no economic evaluation for the application of this drug.Conclusion Live Combined Bifidobacterium and Lactobacillus have a wide range of indications,good efficacy and safety,but its economy needs to be further studied.